Illumina Oncology - Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer

November 14, 2022

Isabelle Ray-Coquard, MD, PhD, explains how comprehensive genomic profiling (CGP) simultaneously provides HRD and _BRCA_ status in ovarian cancer patients. She presents the case of a patient who benefited from CGP testing for these biomarkers and discusses how CGP can detect other actionable mutations. Dr. Ray-Coquard is a medical oncologist at the Centre Léon Bérard, France, professor of medicine at the Université Claude Bernard Lyon 1, and president of the Gineco Group. Listen to the podcast episode to learn about the recent results of the PAOLA-1 trial: Learn about _NTRK_ fusion testing: The Illumina Oncology series is brought to you by Medical Affairs. M-GL-01114 Subscribe to the Illumina video channel A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos View Illumina webinars View Illumina product videos View Illumina support videos Facebook: LinkedIn: Instagram: Twitter:

Share this article on